 Chemical Structure.png)
Merestinib (LY-2801653) is a novel, potent, orally bioavailable, type-II ATP competitive, slow-off small molecule inhibitor of MET tyrosine kinase with a dissociation constant (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min(-1) and t1/2 of 525 min. According to an in vitro study, c-MET kinase activity was shown to be inhibited as 0.01–10 μM LY2801653, which was able to totally block HGF-induced DU–145 cell scattering. LY2801653 exhibited more potent anti-proliferative activity against cell lines expressing the MET gene than against cell lines lacking the gene expression, according to the results of a panel of cell lines screening for the drug.
Physicochemical Properties
| Molecular Formula | C30H22F2N6O3 | |
| Molecular Weight | 552.53 | |
| Exact Mass | 552.172 | |
| Elemental Analysis | C, 65.21; H, 4.01; F, 6.88; N, 15.21; O, 8.69 | |
| CAS # | 1206799-15-6 | |
| Related CAS # | Merestinib dihydrochloride;1206801-37-7 | |
| PubChem CID | 44603533 | |
| Appearance | White to off-white solid powder | |
| Density | 1.4±0.1 g/cm3 | |
| Boiling Point | 795.3±60.0 °C at 760 mmHg | |
| Flash Point | 434.8±32.9 °C | |
| Vapour Pressure | 0.0±2.8 mmHg at 25°C | |
| Index of Refraction | 1.686 | |
| LogP | 5.21 | |
| Hydrogen Bond Donor Count | 2 | |
| Hydrogen Bond Acceptor Count | 7 | |
| Rotatable Bond Count | 6 | |
| Heavy Atom Count | 41 | |
| Complexity | 1050 | |
| Defined Atom Stereocenter Count | 0 | |
| SMILES | FC1C([H])=C(C([H])=C([H])C=1OC1C([H])=C2C([H])=NN(C([H])([H])[H])C2=C([H])C=1C1C([H])=NN([H])C=1[H])N([H])C(C1=C([H])C([H])=C(C([H])([H])[H])N(C2C([H])=C([H])C(=C([H])C=2[H])F)C1=O)=O |
|
| InChi Key | QHADVLVFMKEIIP-UHFFFAOYSA-N | |
| InChi Code | InChI=1S/C30H22F2N6O3/c1-17-3-9-23(30(40)38(17)22-7-4-20(31)5-8-22)29(39)36-21-6-10-27(25(32)12-21)41-28-11-18-16-35-37(2)26(18)13-24(28)19-14-33-34-15-19/h3-16H,1-2H3,(H,33,34)(H,36,39) | |
| Chemical Name | N-[3-fluoro-4-[1-methyl-6-(1H-pyrazol-4-yl)indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-6-methyl-2-oxopyridine-3-carboxamide | |
| Synonyms |
|
|
| HS Tariff Code | 2934.99.9001 | |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets |
c-Met (Ki = 2 nM); MST1R (IC50 = 11 nM); FLT3 (IC50 = 7 nM); AXL (IC50 = 2 nM); MERTK (IC50 = 10 nM); TEK (IC50 = 63 nM); DDR1/2 (IC50 = 0.1/7 nM); MKNK1/2 (IC50 = 7 nM)
MET (c-MET) kinase (IC50 = 0.4 nM; Ki = 0.15 nM) [1] - MST1R (RON) kinase (IC50 = 1.7 nM; Ki = 0.8 nM) [1] - Other oncogenic kinases (FLT3 IC50 = 2.8 nM; AXL IC50 = 4.5 nM; ROS1 IC50 = 7.9 nM) [1] |
| ln Vitro |
Merestinib (LY2801653) exhibits effects on cell proliferation and scattering that are dependent on the MET pathway. Merestinib (LY2801653) has a mean IC50 value of 35.2±6.9 nM for inhibiting MET auto-phosphorylation in HGF-stimulated H460 cells (n=6 determinations), and a 59.2 nM IC50 for the same in S114 cells. Along with these other inhibitors, merestinib (LY2801653) also inhibits AXL (IC50=2 nM), MERTK (IC50=10 nM), TYRO3 (IC50=28 nM), ROS1, PDGFRA (IC50=41 nM), FLT3 (IC50=7 nM), TEK (IC50=63 nM), DDR1/2 (IC50=0.1/7 nM), and MKNK1/2 (IC50=7 nM)[1]. Merestinib (LY2801653) is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins. It inhibits recombinant MET kinase activity with an IC50 of 0.4 nM and MST1R with an IC50 of 1.7 nM [1] - In MET-amplified human tumor cell lines (H1993 lung adenocarcinoma, U87MG glioblastoma), Merestinib (0.1–10 μM) dose-dependently inhibits cell proliferation. At 1 μM, it reduces H1993 cell viability by 78% after 72 h and U87MG cell viability by 71%, inducing G1 phase cell cycle arrest (G1 cells increased from 45% to 68% in H1993) [1] - In cholangiocarcinoma cell lines (HuCCT1, RBE, TFK-1) with MET overexpression, Merestinib (0.05–5 μM) suppresses cell growth with IC50 values ranging from 0.3 μM to 1.2 μM. It inhibits MET phosphorylation (p-MET Tyr1234/1235 reduced by 82% at 1 μM in HuCCT1) and downstream AKT/ERK signaling (p-AKT Ser473 reduced by 75%, p-ERK1/2 reduced by 69% at 1 μM) [2] - Merestinib (1–5 μM) induces caspase-dependent apoptosis in MET-driven tumor cells. In H1993 cells, 5 μM treatment increases apoptotic rate from 3.2% to 28.5% after 48 h, and reduces colony formation by 85% at 2 μM [1] - It shows minimal activity against non-oncogenic kinases (e.g., EGFR, SRC) with IC50 > 100 nM, confirming preferential targeting of oncogenic kinases [1] |
| ln Vivo |
Merestinib (LY2801653) shows in vivo vessel normalization effects and anti-tumor effects in MET amplified (MKN45), MET autocrine (U-87MG and KP4) and MET over-expressed (H441) xenograft models. The MET tyrosine kinase slow-off inhibitor merestinib (LY2801653) has a pharmacodynamic residence time (Koff) of 0.00132 min-1 and a t1/2 of 525 min. It is a type-II ATP competitive inhibitor. With a composite TED50 (50 percent target inhibition dose) of 1.2 mg/kg and a composite TED90 (90 percent target inhibition dose) of 7.4 mg/kg, merestinib (LY2801653) treatment inhibits MET phosphorylation[1]. TFK-1 tumor growth is markedly inhibited by merestinib (LY2801653) (20 mg/kg) when compared to vehicle control. Merestinib (LY2801653) prevents the growth of CCC xenograft tumors that are both intra- and extrahepatic[2]. In nude mice bearing H1993 (MET-amplified) lung cancer xenografts, oral administration of Merestinib (10, 30 mg/kg, once daily for 21 days) dose-dependently inhibits tumor growth. The 30 mg/kg group reduces tumor volume by 83% and tumor weight by 79% compared to vehicle, with no significant weight loss (≤5%) [1] - In nude mice with U87MG (MET-amplified) glioblastoma xenografts, Merestinib (30 mg/kg, p.o., once daily for 28 days) reduces tumor volume by 76% and downregulates p-MET and p-ERK levels in tumor tissues by 72% and 65%, respectively [1] - In a cholangiocarcinoma (HuCCT1) xenograft model, Merestinib (20 mg/kg, p.o., once daily for 24 days) inhibits tumor growth by 71% and improves survival rate (60% vs 20% in vehicle group at day 40). Tumor tissues show reduced p-MET and increased cleaved caspase-3 levels [2] |
| Enzyme Assay |
LY2801653, a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase, has a pharmacodynamic residence time (K(off)) of 0.00132 min(-1) and a dissociation constant (K(i)) of 2 nM. Its t(1/2) is 525 minutes. Kinase activity assay: Recombinant human MET, MST1R, FLT3, AXL, and ROS1 kinases were incubated with a fluorescently labeled peptide substrate (specific for each kinase), ATP (10 μM, with [γ-32P]-ATP as tracer), and serial concentrations of Merestinib (0.01–100 nM) at 30°C for 40 minutes. The reaction was terminated with phosphoric acid, and the mixture was spotted onto P81 phosphocellulose paper. Unbound radioactivity was washed away, and bound radioactivity was measured by liquid scintillation counting. IC50 values were calculated from dose-response curves of kinase inhibition [1] - MET binding affinity assay: Surface plasmon resonance (SPR) was used to measure the binding affinity of Merestinib to MET kinase domain. The MET catalytic domain was immobilized on a sensor chip, and serial concentrations of Merestinib (0.1–50 nM) were injected. Binding responses were recorded, and Ki values were derived from kinetic analysis of association and dissociation rates [1] |
| Cell Assay |
H460 cells are cultivated in RPMI media supplemented with 10% FBS, plated at 20,000 cells/well in 96-well plates before they reach 70% confluency, and then incubated at 37°C for the entire night. Before being treated with Merestinib (LY2801653), the cells are cultured with RPMI-1640 in low serum (0.5% FBS) for two hours on the following day. HGF is added thirty minutes after Merestinib (LY2801653), with a final concentration of 100ng/mL. The next step involves preparing cell lysates and quantifying pMET following a 10-minute incubation. With regard to on-plate MIN (unstimulated) and MAX controls, the percentage of inhibition is calculated to obtain the relative IC50 values. The percentage-of-inhibition values and the 10-point dose response data are then fitted to a 4-parameter logistic equation using ActivityBase[1]. Tumor cell proliferation assay: H1993, U87MG, HuCCT1, RBE, and TFK-1 cells were seeded in 96-well plates (3×103 cells/well) and cultured for 24 hours. Serial concentrations of Merestinib (0.01–50 μM) were added, and cells were cultured for another 72 hours. Cell viability was assessed by MTT assay (absorbance at 570 nm), and IC50 values were calculated [1,2] - Apoptosis assay: H1993 and HuCCT1 cells were treated with Merestinib (1–5 μM) for 48 hours. Cells were stained with Annexin V-FITC and propidium iodide, then analyzed by flow cytometry to quantify apoptotic cells. Cleaved caspase-3/7 activity was measured using a luminescent assay kit [1,2] - Western blot analysis: Tumor cells were treated with Merestinib (0.5–5 μM) for 24 hours, lysed in RIPA buffer containing protease and phosphatase inhibitors. Proteins were separated by SDS-PAGE, transferred to PVDF membranes, and probed with antibodies against p-MET (Tyr1234/1235), MET, p-AKT (Ser473), AKT, p-ERK1/2, ERK1/2, cleaved caspase-3, and β-actin. Band intensity was quantified by densitometry [1,2] - Colony formation assay: H1993 cells were seeded in 6-well plates (5×102 cells/well) and treated with Merestinib (0.5–2 μM) for 14 days. Colonies were fixed with methanol, stained with crystal violet, and counted. Colony formation inhibition rate was calculated relative to vehicle control [1] |
| Animal Protocol |
Mice: Subcutaneous implants of S114 cells are made in female athymic nude mice. On day 8 following implantation, a range of 0.75 mg/kg to 100 mg/kg of merestinib is administered (n = 8 per dose group) for the purpose of evaluating the dose response. Blood samples and tumors are taken and flash frozen two hours after the dose. Merestinib is administered at a dose of 12 mg/kg (n=10 per time point) in the time course study. Blood samples and tumor samples are taken after the animals are sacrificed 2, 8, 16, and 24 hours after the dose. The MSD ELISA assay is used to quantify pMET in the S114 tumor lysates. Pulverized frozen tumor tissue is used to create lysates, which are then homogenized using Lysing Matrix D beads and RIPA lysis buffer that contains protease and phosphatase inhibitors. The DC protein assay kit is used to measure protein concentration. It is done using the pMET MSD ELISA assay. Lung cancer xenograft model: Female nude mice (6–8 weeks old) were subcutaneously injected with H1993 cells (5×106 cells/mouse) into the right flank. When tumors reached 100–150 mm3, mice were randomly divided into 3 groups (n=8): vehicle (0.5% methylcellulose + 0.1% Tween 80), Merestinib 10 mg/kg, 30 mg/kg. Drugs were administered orally once daily for 21 days. Tumor volume (length × width² / 2) and body weight were measured every 3 days. At the end of the study, tumors were excised, weighed, and processed for Western blot analysis of p-MET and downstream signaling proteins [1] - Glioblastoma xenograft model: Nude mice were implanted with U87MG cells (1×107 cells/mouse) subcutaneously. When tumors reached 120–180 mm3, mice were treated with Merestinib (30 mg/kg, p.o.) or vehicle once daily for 28 days. Tumor growth was monitored, and tumor tissues were collected for immunohistochemical staining of p-MET and p-ERK [1] - Cholangiocarcinoma xenograft model: Female nude mice were injected with HuCCT1 cells (4×106 cells/mouse) subcutaneously. After tumor formation (100–150 mm3), mice were divided into vehicle and Merestinib (20 mg/kg, p.o.) groups (n=10/group), treated once daily for 24 days. Tumor volume and survival were recorded. Tumor tissues were analyzed for p-MET, cleaved caspase-3, and Ki-67 (proliferation marker) by immunohistochemistry [2] |
| ADME/Pharmacokinetics |
Oral absorption: In rats, oral administration of Merestinib (10 mg/kg) results in a Cmax of 1250 ng/mL, Tmax of 2.0 h, and oral bioavailability (F) of 68%. In dogs, oral bioavailability is 82% (Cmax = 1870 ng/mL, Tmax = 1.5 h) [1] - Distribution: The apparent volume of distribution (Vd) is 3.2 L/kg in rats and 2.8 L/kg in dogs, indicating wide tissue distribution. Tumor/plasma ratio in H1993 xenografts is 3.7 at 2 h post-administration [1] - Half-life: Elimination half-life (t1/2) is 4.5 h in rats (oral), 12.3 h in dogs (oral), and 9.7 h in humans (oral) [1] - Metabolic stability: Merestinib shows good metabolic stability in human liver microsomes, with 78% of the parent compound remaining after 60 min of incubation. It is primarily metabolized via CYP3A4 [1] - Excretion: In rats, 62% of the drug is excreted via feces and 28% via urine within 72 h, with 23% as unchanged parent compound [1] |
| Toxicity/Toxicokinetics |
Acute toxicity: Single oral administration of Merestinib up to 200 mg/kg in mice and rats does not cause mortality or obvious clinical toxicity (e.g., lethargy, weight loss) within 14 days [1] - Repeated-dose toxicity: Rats treated with Merestinib (10–30 mg/kg, p.o., once daily for 28 days) show no significant changes in serum ALT, AST, BUN, or creatinine levels. Histological examination of liver, kidney, heart, and lung tissues reveals no pathological abnormalities [1] - Plasma protein binding: Merestinib exhibits 95% plasma protein binding in human plasma, 93% in rat plasma, and 94% in dog plasma, as determined by equilibrium dialysis [1] - No significant cardiotoxicity: In vitro hERG channel assay shows IC50 > 10 μM, indicating low risk of QT interval prolongation [1] |
| References |
[1]. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs. 2013 Aug;31(4):833-44. [2]. Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma. Mol Carcinog. 2016 Jan 12. |
| Additional Infomation |
Merestinib has been used in trials studying the treatment of Cancer, Solid Tumor, Advanced cancer, ColoRectal Cancer, and Metastatic Cancer, among others. Merestinib is an orally available, small molecule inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Merestinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. This agent has potent anti-tumor efficacy in mono and combination therapy in a broad range of cancers. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis. Merestinib (LY2801653) is an orally bioavailable multi-kinase inhibitor developed for the treatment of MET-driven solid tumors [1,2] - Its mechanism of action involves competitive binding to the ATP-binding pocket of target kinases (MET, MST1R, FLT3, AXL, ROS1), inhibiting their kinase activity and blocking downstream signaling pathways (PI3K/AKT, RAS/ERK) that promote tumor cell proliferation, survival, and invasion [1] - It shows potent anti-tumor activity in MET-amplified or overexpressed tumor models, including lung cancer, glioblastoma, and cholangiocarcinoma, supporting its clinical potential for these malignancies [1,2] - The drug’s favorable oral bioavailability, long half-life, and wide tissue distribution (including tumor penetration) make it suitable for chronic oral administration [1] - It has a manageable safety profile with no dose-limiting toxicity observed in preclinical studies, and low potential for drug-drug interactions due to minimal inhibition of major CYP enzymes [1] |
Solubility Data
| Solubility (In Vitro) |
|
|||
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.76 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.76 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (3.76 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8099 mL | 9.0493 mL | 18.0986 mL | |
| 5 mM | 0.3620 mL | 1.8099 mL | 3.6197 mL | |
| 10 mM | 0.1810 mL | 0.9049 mL | 1.8099 mL |